Quantum BioPharma (NASDAQ: $QNTM)

Canada · Pharmaceuticals

Quantum BioPharma Ltd is a Canadian biopharmaceutical company based in Toronto, focused on developing innovative drug candidates and biotech solutions for neurodegenerative, neuropsychiatric, inflammatory, and metabolic disorders. Founded in 1998, the company operates through two main segments: Biopharmaceutical Innovation and Strategic Investments. Its mission is to enhance the quality of life for patients by creating novel therapies for complex brain and inflammatory disorders. The company's flagship therapeutic candidate, Lucid-MS, is designed to prevent and reverse myelin degradation in multiple sclerosis and is currently in Phase 2 clinical trials. Other drug candidates include FSD-PEA for inflammatory diseases, Lucid-PSYCH for major depressive disorder, and unbuzzd™, a dietary supplement aimed at accelerating alcohol metabolism. Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, providing a stable income stream to support its research and development activities. The leadership team brings extensive experience in biopharmaceutical development and consumer product marketing.